| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/05/2011 | WO2011050457A1 Stabilized formulation for oral administration of therapeutic agents and related methods |
| 05/05/2011 | WO2011050397A1 Novel enteric combination therapy |
| 05/05/2011 | WO2011050394A1 Methods and compositions for the treatment of osteoarticular disease |
| 05/05/2011 | WO2011031974A9 Acridine analogs in the treatment of gliomas |
| 05/05/2011 | WO2011029639A3 Compounds and methods for treating neoplasia |
| 05/05/2011 | WO2011027222A3 Immunogenic compositions including tlr activity modulators |
| 05/05/2011 | WO2011025938A3 Raf inhibitor compounds and methods of use thereof |
| 05/05/2011 | WO2011025706A3 Heterocyclic amide compounds as protein kinase inhibitors |
| 05/05/2011 | WO2011021230A3 Complexes for treatment and/or prophylaxis of parasitic infections |
| 05/05/2011 | WO2011021221A3 Compositions for spinal cord injury |
| 05/05/2011 | WO2011019423A3 Modulation of pilr receptors to treat microbial infections |
| 05/05/2011 | WO2011017484A3 Sublingual and buccal film compositions |
| 05/05/2011 | WO2011009873A3 New form of the aminoindan mesylate derivative rasaginline mesylate |
| 05/05/2011 | WO2011006886A3 Azole derivatives as agricultural fungicides |
| 05/05/2011 | WO2011006803A9 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition |
| 05/05/2011 | WO2011006794A9 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors |
| 05/05/2011 | WO2011005574A9 Compositions and methods for regulating chondrocyte proliferation in bone disorders |
| 05/05/2011 | WO2011005515A3 Bis-trifluoromethyl honokiol analogs and their use in treating cancers |
| 05/05/2011 | WO2011000811A3 Pharmaceutical solutions for infusion |
| 05/05/2011 | WO2010151737A3 Heterocyclic compounds and their uses as inhibitors of pi3 k activity |
| 05/05/2011 | WO2010151565A3 Combination therapies for the treatment of obesity |
| 05/05/2011 | WO2010151503A3 Combination therapies for the treatment of obesity |
| 05/05/2011 | WO2010148007A3 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| 05/05/2011 | WO2010147830A3 Aminothiazole modulators of beta-3-adrenoreceptor |
| 05/05/2011 | WO2010147430A3 Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same |
| 05/05/2011 | WO2010146568A3 Bifidobacteria for treating diabetes and related conditions |
| 05/05/2011 | WO2010146059A3 Biomarkers for igf-1r inhibitor therapy |
| 05/05/2011 | WO2010139981A3 Processes for preparing crystalline forms of dasatinib |
| 05/05/2011 | WO2010139979A3 Processes for preparing crystalline forms of dasatinib |
| 05/05/2011 | WO2010139585A3 Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide |
| 05/05/2011 | WO2010138588A9 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 05/05/2011 | WO2010128525A8 A formulation of ivabradine for treating the cardiovascular disease |
| 05/05/2011 | WO2010128050A3 Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds |
| 05/05/2011 | WO2010110685A3 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| 05/05/2011 | WO2010039997A9 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| 05/05/2011 | WO2010031248A8 Thiazolium salt compound and the use of treating the protein aging disease |
| 05/05/2011 | WO2010029436A3 Novel solid state forms of ranolazine salts |
| 05/05/2011 | WO2009072004A3 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| 05/05/2011 | WO2009072002A3 Bisphenols in cancer therapy |
| 05/05/2011 | WO2009071990A3 No-donating cordicosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties |
| 05/05/2011 | WO2009027838A3 Kinamycin f for cancer treatment |
| 05/05/2011 | WO2005060456A9 Method for treating adamts-5-associate disease |
| 05/05/2011 | US20110107442 Treatment of Male Sexual Dysfunction |
| 05/05/2011 | US20110107440 Skin cancer associated micrornas |
| 05/05/2011 | US20110106241 Compositions and methods for inhibiting sphingosine kinase |
| 05/05/2011 | US20110106006 Implantable device for long-term delivery of drugs |
| 05/05/2011 | US20110105996 Methods for scar prevention |
| 05/05/2011 | US20110105959 Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway |
| 05/05/2011 | US20110105748 Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 05/05/2011 | US20110105747 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| 05/05/2011 | US20110105626 Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
| 05/05/2011 | US20110105625 Ophthalmic composition for contact lens |
| 05/05/2011 | US20110105624 Endipalene formulations in the treatment of psoriasis |
| 05/05/2011 | US20110105623 Use of methylsulfonylmethane (msm) to modulate microbial activity |
| 05/05/2011 | US20110105622 Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses |
| 05/05/2011 | US20110105621 Method of reducing brain cell damage, inflammation or death |
| 05/05/2011 | US20110105620 Organic compounds |
| 05/05/2011 | US20110105619 Amorphous bupropion hydrobromide and preparation thereof |
| 05/05/2011 | US20110105618 Novel modulators of protein kinase signaling |
| 05/05/2011 | US20110105617 Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof |
| 05/05/2011 | US20110105616 Novel lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
| 05/05/2011 | US20110105615 Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 05/05/2011 | US20110105614 High Concentration Baclofen Preparations |
| 05/05/2011 | US20110105613 Moisture resistant container systems for rapidly bioavailable dosage forms |
| 05/05/2011 | US20110105611 Use of maslinic acid for the treatment of pathologies and their symptoms through the inhibition of cox-2 |
| 05/05/2011 | US20110105610 Phospholipase A2 Inhibitors and their Use in Treating Neurological Injury and Disease |
| 05/05/2011 | US20110105609 Alleviating oxidative stress disorders with pufa derivatives |
| 05/05/2011 | US20110105608 Modulators of nuclear receptor co-regulatory protein binding |
| 05/05/2011 | US20110105607 Lipophilic diesters of chelating agent for inhibition of enzyme activity |
| 05/05/2011 | US20110105606 Compositions and methods affecting the signaling pathways of LRP receptors |
| 05/05/2011 | US20110105605 Method of preparing a latanoprost ophthalmic solution and the resulting solution |
| 05/05/2011 | US20110105603 Compositions and methods for treating beta-amyloid related diseases |
| 05/05/2011 | US20110105602 Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| 05/05/2011 | US20110105601 Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock |
| 05/05/2011 | US20110105600 Synergistic composition of (-)-hydroxycitric acid with monoterpene and a method to enhance satiety |
| 05/05/2011 | US20110105599 Therapeutic or preventive agents for ischemic neuropathy |
| 05/05/2011 | US20110105598 Process for Preparation of Taxane Derivatives |
| 05/05/2011 | US20110105597 Modulation of pathogenicity |
| 05/05/2011 | US20110105596 Compositions and methods for prognosis of ovarian cancer |
| 05/05/2011 | US20110105595 Novel promoter and viral vector containing the same |
| 05/05/2011 | US20110105594 Palatable nutritional composition comprising a nucleotide and/or a nucleoside and a taste masking agent |
| 05/05/2011 | US20110105593 MicroRNA-Formatted Multitarget Interfering RNA Vector Constructs and Methods of Using The Same |
| 05/05/2011 | US20110105591 siRNA COMPOUNDS FOR INHIBITING NRF2 |
| 05/05/2011 | US20110105590 Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes |
| 05/05/2011 | US20110105589 Apoptosis inducer |
| 05/05/2011 | US20110105588 Compositions comprising notch1 sirna and methods of use thereof |
| 05/05/2011 | US20110105587 Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases |
| 05/05/2011 | US20110105586 Compositions and their uses directed to gemin genes |
| 05/05/2011 | US20110105585 METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF |
| 05/05/2011 | US20110105584 Rtp80il sirna compounds and methods of use thereof |
| 05/05/2011 | US20110105583 Methods of using mir34 as a biomarker for tp53 functional status |
| 05/05/2011 | US20110105582 Composition for inhibiting function of human flt3 |
| 05/05/2011 | US20110105581 Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| 05/05/2011 | US20110105580 Novel polymorphic forms of sunitinib base |
| 05/05/2011 | US20110105578 Substituted Imidazole Derivatives And Methods Of Use Thereof |
| 05/05/2011 | US20110105575 Method of treatment of hereditary hemochromatosis |
| 05/05/2011 | US20110105574 Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| 05/05/2011 | US20110105573 Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
| 05/05/2011 | US20110105572 Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| 05/05/2011 | US20110105571 Opioid Receptor Antagonists |